Published in Lancet on May 13, 1995
Recent advances in the management of unstable angina and non-Q-wave myocardial infarction. Br J Clin Pharmacol (1998) 0.75
Heparin in unstable angina. Lancet (1995) 0.75
Heparin in unstable angina. Lancet (1995) 0.75
Left superior vena cava persistence in patients undergoing pacemaker or cardioverter-defibrillator implantation: a 10-year experience. Chest (2001) 5.12
The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med (1995) 4.61
Ability of whole blood aggregometer to detect platelet hyperaggregability. Am J Clin Pathol (1989) 3.30
High prevalence of mild hyperhomocysteinemia in patients with abdominal aortic aneurysm. J Vasc Surg (2000) 2.27
Importance of dural ectasia in phenotypic assessment of Marfan's syndrome. Lancet (1999) 2.20
Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA (1999) 2.08
Physical activity and risk of cognitive decline: a meta-analysis of prospective studies. J Intern Med (2010) 2.04
Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Circ Res (2001) 1.92
Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost (2007) 1.91
Dietary habits, lifestyle and cardiovascular risk factors in a clinically healthy Italian population: the 'Florence' diet is not Mediterranean. Eur J Clin Nutr (2005) 1.85
Improving healthcare worker hand hygiene adherence before patient contact: a before-and-after five-unit multimodal intervention in Tuscany. Qual Saf Health Care (2009) 1.68
Interatrial septum pacing: a new approach to prevent recurrent atrial fibrillation. J Interv Card Electrophysiol (1999) 1.68
Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol (1992) 1.66
Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation (1994) 1.61
Effects of the Dor procedure on left ventricular dimension and shape and geometric correlates of mitral regurgitation one year after surgery. J Thorac Cardiovasc Surg (2001) 1.59
Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart (2005) 1.57
Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant (2005) 1.55
Wide spectrum of presentation and variable outcomes of isolated left ventricular non-compaction. Heart (2006) 1.53
Searching for a better assessment of the individual coronary risk profile. The role of angiotensin-converting enzyme, angiotensin II type 1 receptor and angiotensinogen gene polymorphisms. Eur Heart J (2000) 1.53
Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab (2008) 1.46
Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis. J Hypertens (1998) 1.46
Evidence for the existence of a functional cardiac renin-angiotensin system in humans. Circulation (1996) 1.45
[Is evidence-based medicine really a craze? Surely it is fashionable to criticize it. A methodologic comment from the Centro Italiano per la Medicina Basata sulle Prove (Italian Center for Proof-Based Medicine)]. Ital Heart J Suppl (2000) 1.45
Prevalence of factor V Leiden mutation in non-European populations. Thromb Haemost (1997) 1.45
Silent ischemia in unstable angina is related to an altered cardiac norepinephrine handling. Circulation (1993) 1.44
Percutaneous transluminal coronary angioplasty procedure is associated to a decrease in transforming growth factor beta 1 levels. Thromb Haemost (1999) 1.42
Malignant vasovagal syncope: a randomised trial of metoprolol and clonidine. Heart (1997) 1.42
Early out-of-hospital lidocaine administration decreases the incidence of primary ventricular fibrillation in acute myocardial infarction. J Emerg Med (1994) 1.41
Coronary stenting with the half (disarticulated) Palmaz-Schatz stent: immediate results and six-month follow-up. Cathet Cardiovasc Diagn (1997) 1.40
The role of cysteine and homocysteine in venous and arterial thrombotic disease. Am J Clin Pathol (2001) 1.38
Increased cardiac sympathetic activity and insulin-like growth factor-I formation are associated with physiological hypertrophy in athletes. Circ Res (2001) 1.26
Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J (2010) 1.25
Acute T-cell activation is detectable in unstable angina. Circulation (1997) 1.19
Differential inhibition of prostacyclin production and platelet aggregation by aspirin. Lancet (1979) 1.16
Polarization of PPD-specific T-cell response of patients with tuberculosis from Th0 to Th1 profile after successful antimycobacterial therapy or in vitro conditioning with interferon-alpha or interleukin-12. Am J Respir Cell Mol Biol (2001) 1.12
Nightmares and sleep disturbances with simvastatin and metoprolol. Ann Pharmacother (2001) 1.12
Transient intermittent lymphocyte activation is responsible for the instability of angina. Circulation (1992) 1.11
Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol (1993) 1.10
A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm. Int J Cardiol (1994) 1.09
Clinical results of the Verapamil inHypertension and Atherosclerosis Study. VHAS Investigators. J Hypertens (1997) 1.09
Cardiac growth factors in human hypertrophy. Relations with myocardial contractility and wall stress. Circ Res (1999) 1.08
A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J (1999) 1.07
The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens (1998) 1.06
A novel Alu-like element rearranged in the dystrophin gene causes a splicing mutation in a family with X-linked dilated cardiomyopathy. Am J Hum Genet (1998) 1.06
Opposite effects of interleukin 10 common gene polymorphisms in cardiovascular diseases and in successful ageing: genetic background of male centenarians is protective against coronary heart disease. J Med Genet (2004) 1.04
Pulmonary arterial hypertension associated to connective tissue diseases. Lupus (2005) 1.03
Periodontal health improves systemic inflammatory and haemostatic status in subjects with coronary heart disease. J Clin Periodontol (2005) 1.03
Physiologic role of coronary PGI2 and PGE2 in modulating coronary vascular response to sympathetic stimulation. Am Heart J (1990) 1.02
Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb Haemost (1998) 1.02
Amlodipine reduces transient myocardial ischemia in patients with coronary artery disease: double-blind Circadian Anti-Ischemia Program in Europe (CAPE Trial). J Am Coll Cardiol (1994) 1.00
N-acetylcysteine reduces methemoglobin in vitro. Ann Emerg Med (1996) 1.00
Dynamic electrophysiological behavior of human atria during paroxysmal atrial fibrillation. Circulation (1995) 0.99
Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study. Atherosclerosis (2006) 0.99
Heterogeneity in world distribution of the thermolabile C677T mutation in 5,10-methylenetetrahydrofolate reductase. Am J Hum Genet (1998) 0.99
Benefits in projected pacemaker longevity and in pacing related costs conferred by automatic threshold tracking. Pacing Clin Electrophysiol (2000) 0.99
Evaluation of the pulse-contour method of determining stroke volume in man. Circulation (1972) 0.98
Atrial premature beats coupling interval determines lone paroxysmal atrial fibrillation onset. Int J Cardiol (1992) 0.97
Transvenous low energy internal cardioversion for atrial fibrillation: a review of clinical applications and future developments. Pacing Clin Electrophysiol (2001) 0.96
Evaluation of clotting and fibrinolytic activation after protracted physical exercise. Thromb Res (1998) 0.96
Aspirin effect on early and late changes in acute lung injury in sheep. Intensive Care Med (1993) 0.96
Protein Z-dependent protease inhibitor and protein Z in peripheral arterial disease patients. J Thromb Haemost (2009) 0.95
Effect of medium-term supplementation with a moderate dose of n-3 polyunsaturated fatty acids on blood pressure in mild hypertensive patients. Thromb Res (1998) 0.95
ACE DD genotype: a predisposing factor for abdominal aortic aneurysm. Eur J Vasc Endovasc Surg (2005) 0.94
The value of lung ultrasound monitoring in H1N1 acute respiratory distress syndrome. Anaesthesia (2009) 0.94
Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized, controlled trial. Ann Intern Med (1997) 0.94
The high prevalence of thermolabile 5-10 methylenetetrahydrofolate reductase (MTHFR) in Italians is not associated to an increased risk for coronary artery disease (CAD). Thromb Haemost (1998) 0.93
Early Lactococcus lactis endocarditis after mitral valve repair: a case report and literature review. Infection (2012) 0.93
Increased fibrinopeptide A formation and thromboxane A2 production in patients with ischemic heart disease: relationships to coronary pathoanatomy, risk factors, and clinical manifestations. Am Heart J (1981) 0.92
Prostacyclin and thromboxane A2 formation in response to adrenergic stimulation in humans: a mechanism for local control of vascular response to sympathetic activation? Cardiovasc Res (1981) 0.92
Role of pharmacologic tests in the treatment of primary pulmonary hypertension. Am J Cardiol (1995) 0.92
Reduced prostacyclin production in patients with different manifestations of ischemic heart disease. Am J Cardiol (1982) 0.92
Partial anomalous venous return associated with intact atrial septum and persistent left superior vena cava: a case report and literature review. Cardiologia (1999) 0.92
Clinical value of multidetector CT coronary angiography as a preoperative screening test before non-coronary cardiac surgery. Heart (2006) 0.92
Atherosclerosis and calcium antagonists: the VHAS. The Verapamil-Hypertension Atherosclerosis Study (VHAS) Investigators. J Hum Hypertens (1992) 0.92
Anomalous origin of the circumflex artery and patent foramen ovale: a rare cause of myocardial ischaemia after percutaneous closure of the defect. Heart (2003) 0.91
Age-related changes in the hemostatic system. Int J Clin Lab Res (1993) 0.91
Increased intralymphocytic sodium content in essential hypertension: an index of impaired Na+ cellular metabolism. Clin Sci (Lond) (1981) 0.91
Leisure time but not occupational physical activity significantly affects cardiovascular risk factors in an adult population. Eur J Clin Invest (2007) 0.91
Fibrillin-1 (FBN1) gene frameshift mutations in Marfan patients: genotype-phenotype correlation. Clin Genet (2001) 0.91
Pulmonary hypertension associated with long-standing thrombocytosis. Chest (1991) 0.91
Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols. Pacing Clin Electrophysiol (1998) 0.91
Safety, feasibility, and prognostic implications of pharmacologic stress echocardiography in 1482 patients evaluated in an ambulatory setting. Am Heart J (2001) 0.91
Reduction in deep vein thrombosis incidence in intensive care after a clinician education program. J Thromb Haemost (2009) 0.90
Enhanced thrombolytic efficacy and reduction of infarct size by simultaneous infusion of streptokinase and heparin. Br Heart J (1990) 0.90
Captopril in mild heart failure: preliminary observations of a long-term, double-blind, placebo-controlled multicentre trial. Postgrad Med J (1986) 0.90